# Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）

> **NCT07005570** · PHASE2 · RECRUITING · sponsor: **Dechang Diao** · enrollment: 86 (estimated)

## Conditions studied

- pMMR/MSS Locally Advanced Rectal Cancer

## Interventions

- **OTHER:** Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab
- **OTHER:** Short-course radiotherapy followed by sequential chemotherapy

## Key facts

- **NCT ID:** NCT07005570
- **Lead sponsor:** Dechang Diao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07005570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07005570, "Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07005570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*